Table 1.
Clinicopathological features of 54 enrolled patients with stage IV colorectal cancer, comprising 28 patients in the study group and 26 in the control group, evaluated using the chi-square test and Wilcoxon rank sum test.
| Total | Study Group | Control Group | ||
|---|---|---|---|---|
| (n = 54) | (n = 28) | (n = 26) | p-value | |
| N | N (%) | N (%) | ||
| Gender | 0.967 # | |||
| Male | 31 | 16 (57.1) | 15 (57.7) | |
| Female | 23 | 12 (42.9) | 11 (42.3) | |
| Age (y/o) * | 0.178 # | |||
| <65 | 36 | 21 (75.0) | 15 (57.7) | |
| ≥65 | 18 | 7 (25.0) | 11 (42.3) | |
| Age (y/o) * | 0.137 ## | |||
| Median ± S.D * | 57.46 ± 12.15 | 62.38 ± 11.72 | ||
| (range) | (30 ~ 79) | (43 ~ 83) | ||
| Stage IV | 0.872 # | |||
| Synchronous | 40 | 21 (75.0) | 19 (73.1) | |
| Metachronous | 14 | 7 (25.0) | 7 (26.9) | |
| Metastasectomy | 0.244 # | |||
| Yes | 12 | 8 (28.6) | 4 (15.4) | |
| No | 42 | 20 (71.4) | 22 (84.6) | |
| Follow-up (months) | 0.117 ## | |||
| Median ± S.D * | 12.39 ± 4.41 | 10.54 ± 3.22 | ||
| (range) | (4 ~ 20) | (4 ~ 16) | ||
| Pre-WBC ** (/μL) | 0.671 ## | |||
| Mean ± S.D * | 7118 ± 2669 | 7330 ± 2960 | ||
| Median | 7065 | 7045 | ||
| Pre-Hgb ** (g/dL) | 0.472 ## | |||
| Mean ± S.D * | 11.89 ± 1.78 | 11.51 ± 1.90 | ||
| Median | 11.80 | 11.45 | ||
| Pre-Platelet (/μL) | 0.952 ## | |||
| Mean ± S.D * | 303,964 ± 99,869 | 300,346 ± 87,945 | ||
| Median | 278,500 | 292,500 | ||
| Pre-GPT ** (U/L) | 0.646 ## | |||
| Mean ± S.D * | 23.54 ± 12.56 | 20.92 ± 6.80 | ||
| Median | 21.50 | 20.50 | ||
| Pre-Cr ** (mg/dL) | 0.591 ## | |||
| Mean ± S.D * | 0.96 ± 0.75 | 0.89 ± 0.26 | ||
| Median | 0.815 | 0.835 | ||
| Pre-CEA ** (ng/mL) | 0.236 ## | |||
| Mean ± S.D * | 989.9 ± 3622.5 | 35.05 ± 60.78 | ||
| Median | 31.38 | 13.92 | ||
| Pre-Body weight (kg) | 0.382 ## | |||
| Mean ± S.D * | 62.39 ± 11.30 | 59.50 ± 11.90 | ||
| Median | 61.45 | 58.00 |
# chi-square test; ## Wilcoxon rank sum test; * y/o: years old; S.D.: standard deviation; ** WBC: white blood count; Hgb: hemoglobin; GPT: glutamic-pyruvic transaminase; Cr: creatinine; CEA: carcinoembryonic antigen.